Spinal Morphine vs. Hydromorphone for Pain Control After Cesarean Delivery


  • Study type

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 15-009421
    NCT ID: NCT02789410
    Sponsor Protocol Number: 15-009421

About this study

Intrathecal (IT) opioids are commonly administered with local anesthetic during spinal anesthesia for post-Cesarean delivery analgesia. Traditionally, IT morphine has been used but the use of IT hydromorphone is growing. Our group recently found the effective dose for postoperative analgesia in 90% patients (ED90) for both IT hydromorphone and IT morphine (IRB # 13-008490). These doses that we found were 75 mcg for hydromorphone and 150 mcg for morphine. Our current proposed study would compare the duration of analgesia of IT morphine vs IT hydromorphone after elective cesarean delivery. Additionally, we will compare each drug on the incidence of nausea and pruritus.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria


  1. ASA physical status II-III women presenting for elective cesarean delivery
  2. Term gestation (37-42 weeks)
  3. Desire to have a spinal anesthesia technique for cesarean delivery


  1. Any contraindication to the administration of a spinal technique for anesthesia
  2. History of intolerance or adverse reaction to opioid medications
  3. Chronic pain syndrome or current opioid use >30 oral morphine equivalents/day
  4. Allergy or intolerance to acetaminophen, ketorolac, ibuprofen, or oxycodone
  5. Current BMI > 50

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Hans Sviggum, M.D.

Closed for enrollment

Contact information:

Hans Sviggum M.D.




Mayo Clinic Footer